Anna Tsimelzon

7.8k total citations · 2 hit papers
62 papers, 5.1k citations indexed

About

Anna Tsimelzon is a scholar working on Oncology, Molecular Biology and Cancer Research. According to data from OpenAlex, Anna Tsimelzon has authored 62 papers receiving a total of 5.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 30 papers in Molecular Biology and 26 papers in Cancer Research. Recurrent topics in Anna Tsimelzon's work include Breast Cancer Treatment Studies (16 papers), Estrogen and related hormone effects (14 papers) and Cancer Cells and Metastasis (12 papers). Anna Tsimelzon is often cited by papers focused on Breast Cancer Treatment Studies (16 papers), Estrogen and related hormone effects (14 papers) and Cancer Cells and Metastasis (12 papers). Anna Tsimelzon collaborates with scholars based in United States, Italy and Switzerland. Anna Tsimelzon's co-authors include Susan G. Hilsenbeck, Jenny C. Chang, C. Kent Osborne, Powel H. Brown, Suzanne A.W. Fuqua, Gordon B. Mills, Syed K. Mohsin, D. Craig Allred, P. O’Connell and Graham M. Poage and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Anna Tsimelzon

61 papers receiving 5.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

2014 936 citations Matthew D. Burstein, Anna Tsimelzon et al. Clinical Cancer Research profile →
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

2003 668 citations Jenny C. Chang, Eric C. Wooten et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anna Tsimelzon United States	33	2.7k	2.6k	2.1k	882	799	62	5.1k
Els M.J.J. Berns Netherlands	40	3.9k 1.5×	2.4k 0.9×	2.3k 1.1×	1.1k 1.3×	671 0.8×	87	6.3k
Vessela N. Kristensen Norway	37	3.2k 1.2×	1.4k 0.5×	2.3k 1.1×	806 0.9×	644 0.8×	132	5.1k
Simone Detre United Kingdom	30	1.6k 0.6×	2.2k 0.9×	1.7k 0.8×	1.3k 1.5×	683 0.9×	63	4.2k
Libero Santarpia Italy	37	3.3k 1.2×	1.8k 0.7×	2.2k 1.1×	425 0.5×	773 1.0×	89	5.4k
Amir A. Jazaeri United States	34	2.6k 1.0×	2.3k 0.9×	1.8k 0.8×	858 1.0×	504 0.6×	169	5.7k
Susan M. Edgerton United States	34	2.8k 1.0×	3.2k 1.2×	1.8k 0.9×	614 0.7×	698 0.9×	62	5.2k
Zhi‐Ming Shao China	33	1.9k 0.7×	1.6k 0.6×	2.0k 0.9×	421 0.5×	687 0.9×	169	4.3k
Pedram Argani United States	34	3.4k 1.3×	1.9k 0.7×	1.5k 0.7×	544 0.6×	553 0.7×	54	5.1k
Jack X. Yu United States	16	3.4k 1.3×	1.8k 0.7×	1.8k 0.9×	484 0.5×	705 0.9×	20	5.2k
Pierre Farmer Switzerland	14	2.4k 0.9×	1.7k 0.7×	2.0k 1.0×	483 0.5×	562 0.7×	26	4.4k

Countries citing papers authored by Anna Tsimelzon

Since Specialization

Citations

This map shows the geographic impact of Anna Tsimelzon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Tsimelzon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Tsimelzon more than expected).

Fields of papers citing papers by Anna Tsimelzon

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Tsimelzon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Tsimelzon. The network helps show where Anna Tsimelzon may publish in the future.

Co-authorship network of co-authors of Anna Tsimelzon

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Tsimelzon. A scholar is included among the top collaborators of Anna Tsimelzon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Tsimelzon. Anna Tsimelzon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hollander, Petra den, Anna Tsimelzon, Jonathan H. Shepherd, et al.. (2016). Phosphatase PTP4A3 Promotes Triple-Negative Breast Cancer Growth and Predicts Poor Patient Survival. Cancer Research. 76(7). 1942–1953. 70 indexed citations

Mazumdar, Abhijit, Graham M. Poage, Jonathan H. Shepherd, et al.. (2016). Analysis of phosphatases in ER-negative breast cancers identifies DUSP4 as a critical regulator of growth and invasion. Breast Cancer Research and Treatment. 158(3). 441–454. 22 indexed citations

Zhang, Mei, Anna Tsimelzon, Cheng Fan, et al.. (2015). Intratumoral Heterogeneity in a Trp53 -Null Mouse Model of Human Breast Cancer. Cancer Discovery. 5(5). 520–533. 54 indexed citations

Rechoum, Yassine, Guowei Gu, Luca Gelsomino, et al.. (2015). Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer. Breast Cancer Research and Treatment. 154(2). 225–237. 44 indexed citations

Burstein, Matthew D., Anna Tsimelzon, Graham M. Poage, et al.. (2014). Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer. Clinical Cancer Research. 21(7). 1688–1698. 936 indexed citations breakdown →

Hartman, Zachary C., Graham M. Poage, Petra den Hollander, et al.. (2013). Growth of Triple-Negative Breast Cancer Cells Relies upon Coordinate Autocrine Expression of the Proinflammatory Cytokines IL-6 and IL-8. Cancer Research. 73(11). 3470–3480. 341 indexed citations

Reineke, Erin L., Brian York, Erin Stashi, et al.. (2012). SRC-2 Coactivator Deficiency Decreases Functional Reserve in Response to Pressure Overload of Mouse Heart. PLoS ONE. 7(12). e53395–e53395. 23 indexed citations

Selever, Jennifer, Guowei Gu, Michael T. Lewis, et al.. (2011). Dicer-Mediated Upregulation of BCRP Confers Tamoxifen Resistance in Human Breast Cancer Cells. Clinical Cancer Research. 17(20). 6510–6521. 45 indexed citations

Loudin, Michael, Jia‐Bin Wang, S. Gurusiddappa, et al.. (2011). Genomic profiling in Down syndrome acute lymphoblastic leukemia identifies histone gene deletions associated with altered methylation profiles. Leukemia. 25(10). 1555–1563. 30 indexed citations

10.

Casà, Angelo, Simeen Malik, ZaWaunyka Lazard, et al.. (2011). Estrogen and insulin-like growth factor-I (IGF-I) independently down-regulate critical repressors of breast cancer growth. Breast Cancer Research and Treatment. 132(1). 61–73. 37 indexed citations

11.

Litzenburger, Beate C., Chad J. Creighton, Anna Tsimelzon, et al.. (2010). High IGF-IR Activity in Triple-Negative Breast Cancer Cell Lines and Tumorgrafts Correlates with Sensitivity to Anti–IGF-IR Therapy. Clinical Cancer Research. 17(8). 2314–2327. 109 indexed citations

12.

Speers, Corey, Anna Tsimelzon, K. Sexton, et al.. (2009). Identification of Novel Kinase Targets for the Treatment of Estrogen Receptor–Negative Breast Cancer. Clinical Cancer Research. 15(20). 6327–6340. 77 indexed citations

13.

Moran, Ana, Anna Tsimelzon, Yong Wu, et al.. (2009). Prevention of Trauma/Hemorrhagic Shock‐Induced Lung Apoptosis by IL‐6‐Mediated Activation of Stat3. Clinical and Translational Science. 2(1). 41–49. 18 indexed citations

14.

Kaipparettu, Benny Abraham, Anna Tsimelzon, Chad J. Creighton, et al.. (2009). SAFB1 Mediates Repression of Immune Regulators and Apoptotic Genes in Breast Cancer Cells. Journal of Biological Chemistry. 285(6). 3608–3616. 31 indexed citations

15.

Allred, D. Craig, Yun Wu, Sufeng Mao, et al.. (2008). Ductal Carcinoma In situ and the Emergence of Diversity during Breast Cancer Evolution. Clinical Cancer Research. 14(2). 370–378. 207 indexed citations

16.

Zhang, Mei, Fariba Behbod, Rachel L. Atkinson, et al.. (2008). Identification of Tumor-Initiating Cells in a p53-Null Mouse Model of Breast Cancer. Cancer Research. 68(12). 4674–4682. 260 indexed citations

17.

Massarweh, Suleiman, C. Kent Osborne, Chad J. Creighton, et al.. (2008). Tamoxifen Resistance in Breast Tumors Is Driven by Growth Factor Receptor Signaling with Repression of Classic Estrogen Receptor Genomic Function. Cancer Research. 68(3). 826–833. 375 indexed citations

18.

Creighton, Chad J., Suleiman Massarweh, Shixia Huang, et al.. (2008). Development of Resistance to Targeted Therapies Transforms the Clinically Associated Molecular Profile Subtype of Breast Tumor Xenografts. Cancer Research. 68(18). 7493–7501. 101 indexed citations

19.

Jatoi, Ismail, Anna Tsimelzon, Heidi L. Weiss, Gary M. Clark, & Susan G. Hilsenbeck. (2005). Hazard rates of recurrence following diagnosis of primary breast cancer. Breast Cancer Research and Treatment. 89(2). 173–178. 65 indexed citations

20.

Chang, Jenny C., Eric C. Wooten, Anna Tsimelzon, et al.. (2003). Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. The Lancet. 362(9381). 362–369. 668 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact